

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Martin F. Stefanic, et al.) Art Unit: 1614  
Serial No.: 10/830,147 ) Examiner: James D. ANDERSON  
Confirmation No.: 7845  
Filed: April 22, 2004  
For: COMBINATIONS FOR THE TREATMENT OF DISEASES  
INVOLVING CELL PROLIFERATION, MIGRATION OR  
APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS  
Docket No.: 01-1464

Via EFS Web  
Commissioner for Patents  
Alexandria, VA 22313-1450

**PETITION UNDER 37 CFR 1.136(a) FOR EXTENSION OF TIME**

Sir:

It is hereby requested that the time for responding to the Action mailed on December 18, 2007, be extended pursuant to 37 CFR 1.136(a) for three (3) months, to maintain the pendency of the above-captioned application until June 18, 2008.

The fee set in 37 CFR 1.17 for this extension of time is \$ 1,050.00. The Commissioner is hereby authorized to charge this and any other fee which may be required, and to credit any overpayment, to Deposit Account No. 02-2955.

Respectfully submitted,

/Mary-Ellen M. Devlin/  
Mary-Ellen M. Devlin  
Attorney for Applicant(s)  
Reg. No. 27,928

Patent Department  
Boehringer Ingelheim Corp.  
900 Ridgebury Road  
P.O. Box 368  
Ridgefield, CT 06877  
Tel: (203) 798-4866  
Fax: (203) 798-4408

Date: June 17, 2008